Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin and Dapagliflozin Effect on EPCs in T2DM
NCT03660683Phase 4Terminated
- Start
- Oct 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin, saxagliptin in type 2 diabetes mellitus (T2DM). Started Oct 2018; status: terminated.
02
Drugs
dapagliflozinsaxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03660683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03660683.